Cargando…
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
Regulation of the androgen receptor (AR) is critical to prostate cancer (PCa) development; therefore, AR is the first line therapeutic target for disseminated tumors. Cell cycle dependent accumulation of cyclin D1 negatively modulates the transcriptional regulation of the AR through discrete, CDK4-i...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852245/ https://www.ncbi.nlm.nih.gov/pubmed/19079343 http://dx.doi.org/10.1038/onc.2008.446 |
_version_ | 1782179926903881728 |
---|---|
author | Schiewer, Matthew J. Morey, Lisa M. Burd, Craig J. Liu, Yuhong Merry, Diane E. Ho, Shuk-Mei Knudsen, Karen E. |
author_facet | Schiewer, Matthew J. Morey, Lisa M. Burd, Craig J. Liu, Yuhong Merry, Diane E. Ho, Shuk-Mei Knudsen, Karen E. |
author_sort | Schiewer, Matthew J. |
collection | PubMed |
description | Regulation of the androgen receptor (AR) is critical to prostate cancer (PCa) development; therefore, AR is the first line therapeutic target for disseminated tumors. Cell cycle dependent accumulation of cyclin D1 negatively modulates the transcriptional regulation of the AR through discrete, CDK4-independent mechanisms. The transcriptional co-repressor function of cyclin D1 resides within a defined motif termed ther repressor domain (RD), and it was hypothesized that this motif could be utilized as a platform to develop new strategies for blocking AR function. Here, we demonstrate that expression of the RD peptide is sufficient to disrupt AR transcriptional activation of multiple, prostate-specific AR target genes. Importantly, these actions are sufficient to specifically inhibit S-phase progression in AR-positive PCa cells, but not in AR-negative cells or tested AR-positive cells of other lineages. As expected, impaired cell cycle progression resulted in a suppression of cell doubling. Additionally, cell death was observed in AR-positive cells that maintain androgen dependence and in a subset of castrate-resistant PCa cells, dependent on Akt activation status. Lastly, the ability of RD to cooperate with existing hormone therapies was examined, which revealed that RD enhanced the cellular response to an AR antagonist. Together, these data demonstrate that RD is sufficient to disrupt AR-dependent transcriptional and proliferative responses in PCa, and can enhance efficacy of AR antagonists, thus establishing the impetus for development of RD-based mimetics. |
format | Text |
id | pubmed-2852245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
record_format | MEDLINE/PubMed |
spelling | pubmed-28522452010-04-09 Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer Schiewer, Matthew J. Morey, Lisa M. Burd, Craig J. Liu, Yuhong Merry, Diane E. Ho, Shuk-Mei Knudsen, Karen E. Oncogene Article Regulation of the androgen receptor (AR) is critical to prostate cancer (PCa) development; therefore, AR is the first line therapeutic target for disseminated tumors. Cell cycle dependent accumulation of cyclin D1 negatively modulates the transcriptional regulation of the AR through discrete, CDK4-independent mechanisms. The transcriptional co-repressor function of cyclin D1 resides within a defined motif termed ther repressor domain (RD), and it was hypothesized that this motif could be utilized as a platform to develop new strategies for blocking AR function. Here, we demonstrate that expression of the RD peptide is sufficient to disrupt AR transcriptional activation of multiple, prostate-specific AR target genes. Importantly, these actions are sufficient to specifically inhibit S-phase progression in AR-positive PCa cells, but not in AR-negative cells or tested AR-positive cells of other lineages. As expected, impaired cell cycle progression resulted in a suppression of cell doubling. Additionally, cell death was observed in AR-positive cells that maintain androgen dependence and in a subset of castrate-resistant PCa cells, dependent on Akt activation status. Lastly, the ability of RD to cooperate with existing hormone therapies was examined, which revealed that RD enhanced the cellular response to an AR antagonist. Together, these data demonstrate that RD is sufficient to disrupt AR-dependent transcriptional and proliferative responses in PCa, and can enhance efficacy of AR antagonists, thus establishing the impetus for development of RD-based mimetics. 2008-12-15 2009-02-19 /pmc/articles/PMC2852245/ /pubmed/19079343 http://dx.doi.org/10.1038/onc.2008.446 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Schiewer, Matthew J. Morey, Lisa M. Burd, Craig J. Liu, Yuhong Merry, Diane E. Ho, Shuk-Mei Knudsen, Karen E. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title | Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title_full | Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title_fullStr | Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title_full_unstemmed | Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title_short | Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer |
title_sort | cyclin d1 repressor domain mediates proliferation and survival in prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852245/ https://www.ncbi.nlm.nih.gov/pubmed/19079343 http://dx.doi.org/10.1038/onc.2008.446 |
work_keys_str_mv | AT schiewermatthewj cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT moreylisam cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT burdcraigj cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT liuyuhong cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT merrydianee cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT hoshukmei cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer AT knudsenkarene cyclind1repressordomainmediatesproliferationandsurvivalinprostatecancer |